KALA BIO (NASDAQ:KALA) Releases Earnings Results, Beats Estimates By $0.50 EPS

KALA BIO (NASDAQ:KALA) issued its earnings results on Tuesday. The company reported ($1.93) earnings per share for the quarter, topping the consensus estimate of ($2.43) by $0.50, Zacks reports.

KALA BIO Trading Down 3.2 %

KALA BIO stock opened at $6.86 on Thursday. KALA BIO has a 1 year low of $4.21 and a 1 year high of $10.97. The firm’s 50 day moving average price is $5.98 and its 200-day moving average price is $6.29. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.07 and a quick ratio of 3.07. The stock has a market cap of $31.61 million, a P/E ratio of -0.55 and a beta of -2.13.

Wall Street Analyst Weigh In

Separately, Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of KALA BIO in a research note on Monday, August 19th.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.